The phase-3b switching study mentioned in #msg-55725398 implies that GILD is thinking about Btripla in the second-line setting following Truvada + a PI in the first line. This is a shrinking market, however, as Intelence and Isentress have been pecking away at the market share of the PI’s in the first line.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.